Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M

BIODESIX INC

2025-Q2 EPS reported -$0.15 revenue$37,976,000

Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).
Gross margin 80% (up 150 bps); net loss $11.5M (+6% YoY); Adjusted EBITDA loss $7.2M.
Reaffirms FY2025 revenue guidance $80-85M; aims for Adjusted EBITDA positive in Q4.
Sales team expanded to 74 reps (+21% YoY); primary care ordering up >100%; digital ordering up 63%.
Development services dollars under contract $12.5M (+54% YoY); ALTITUDE trial enrollment complete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.